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Summary Background Tanibirumab is a fully human mono-
clonal antibody to vascular endothelial growth factor receptor
2 (VEGFR-2).We conducted a first-in-human phase I study of
tanibirumab in patients with solid tumors refractory to stan-
dard chemotherapy. Primary endpoints were evaluating safety,
pharmacokinetics (PKs), estimating maximum-tolerated dose
(MTD) and recommended phase II dose (RP2D).MethodsWe
designed our study to escalate tanibirumab at 9 different dose
levels with a 3 + 3 method and tanibirumab (1–28 mg/kg) was
administered intravenously on D1, 8, 15 in 28-day courses.
Dose limiting toxicities (DLTs) were only assessed during the
first cycle of treatment and response evaluation was per-
formed every 2 cycles. The effects of tanibirumab on several
angiogenic factors were analyzed. Results FromOctober 2011
to September 2013, a total of 26 patients with refractory solid
tumors were enrolled. The median age was 58 years (range,
27–75) and 20 patients were male. The most common tumor
type was colorectal cancer (N = 19) and seven patients had a
history of previous bevacizumab treatment. As hemangioma
continued to occur, the final dose level, 28 mg/kg, was not
performed. DLTs were not found, and the MTD was con-
firmed to be 24 mg/kg. Hemangioma was observed in 16
patients (61.5%), but all were grade 1–2 and disappeared after
discontinuation of the study drug. Among the 18 patients in
the efficacy set, no objective response was observed, but 11
patients showed stable disease. PKs were characterized by
dose-dependent linear exposure and the mean trough concen-
trations exceeded biologically relevant target levels at 12 mg/
kg and above. Serum VEGF, soluble VEGFR-2, and PlGF
increased at the 4 mg/kg dose level and above. Conclusions
Treatment with tanibirumab showed a tolerable toxicity pro-
file and modest clinical efficacy in patients with refractory
solid tumors. A phase II trial of tanibirumab is ongoing now.
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Introduction
Angiogenesis is a complex process that includes endothe-
lial cell proliferation and movement, as well as endothelial
cell-mediated degradation of the extracellular matrix. The
multi-step process of angiogenesis is essential for cancer
progression and metastasis [1]. Vascular endothelial
growth factor (VEGF) is a key regulator of angiogenesis
and is usually up-regulated in cancers [2]. There are two
VEGF receptors responsible for angiogenesis; VEGFR-1,
also known as Flt-1, and VEGFR-2, also known as KDR.
VEGFR-2 is a major mediator of the mitogenic and angio-
genic effects of VEGF signaling [3]. The binding of VEGF
to VEGFR-2 triggers auto-phosphorylation and results in
activation of downstream pathways, including PI3K-AKT
and the RAS-RAF-MEK-MAPK signaling network, which
is essential for stimulating the proliferation, migration and
survival of cancer and endothelial cells.
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Various anti-angiogenic agents have been developed to tar-
get the VEGF pathway. Bevacizumab (Avastin, Roche), a hu-
manized monoclonal immunoglobulin G1 antibody targeting
circulating VEGF, has been shown to improve clinical out-
comes in combination with chemotherapy in various cancer
types, such as colorectal, lung and ovarian cancers [4–9].
Small molecular inhibitors, like sorafenib (Nexavar, Bayer)
and sunitinib (Sutent, Pfizer), targeting VEGFR2 also showed
clinical benefit as single agents for hepatocellular carcinoma
or renal cell carcinoma [10–13]. Recently, ramucirumab
(Cyramza, Lilly), a monoclonal antibody to VEGFR-2,
showed a survival benefit when used solo or in combination
with chemotherapy [14, 15].
Tanibirumab is a fully human monoclonal antibody (IgG1)
derived from a fully human naïve single chain variable frag-
ment (ScFv) phage library. Tanibirumab selectively binds to
VEGFR-2, neutralizes the biological activity of VEGFR-2
and, therefore, blocks angiogenesis and inhibits tumor growth
and metastasis. In mouse xenograft and orthotopic models,
tanibirumab resulted in robust anti-tumor activity as a single
agent, with an efficacious dose range of 0.1–10 mg/kg in
colorectal, breast, lung and glioblastoma tumor models [16].
Consequently, we planned this first-in-human phase I study to
establish the safety profile and maximum-tolerate dose
(MTD) of tanibirumab in patients with advanced solid malig-
nancies. We characterized the pharmacokinetics (PK), phar-
macodynamics (PD) effects on serum VEGFR-A, soluble
VEGFR-2 and PlGF and preformed a preliminary evaluation
of antitumor activity.
Methods
A prospective, single center, open-label study with dose esca-
lation of tanibirumab was conducted in patients with refracto-
ry solid tumors. The study was conducted in accordance with
the Declaration of Helsinki. The study protocol was approved
by the Institutional Review Board at SamsungMedical Center
and registered in clinicaltrial.gov NCT#01660360.
Patient eligibility
Eligibility criteria for study entry were as follows: histologi-
cally confirmed, advanced cancers that failed to respond to at
least one prior regimen or for which there is no standard ther-
apy; evaluable disease (measurable or non-measurable based
on RECIST criteria v 1.1); age > 20 years; ECOG (Eastern
Cooperative Oncology Group) performance status 0–2; life
expectancy of greater than 12 weeks; hemoglobin ≥9.0 g/dL,
absolute neutrophil count ≥1500/μL, platelets ≥100,000/μL,
total bilirubin ≤1.5 times the upper limit of normal, AST/ALT
≤2.5 times the upper limit of normal, serum creatinine
≤1.5 mg/dL, PT-INR ≤1.3 times the upper limit of normal,
aPTT ≤1.5 times the upper limit of normal and Bazett’s cor-
rection QTc < 450 msec in ECG. Patients were excluded from
the study if they had undergone radiotherapy, last chemother-
apy, or major surgery within the 4 weeks prior to entering the
study, had pleural effusion, ascites or leptomeningeal disease
as the only manifestation of the current malignancy, had un-
controlled intercurrent illness, active serious infection, the
presence of gastrointestinal perforation, tracheoesophageal
fistula, grade IV proteinuria, arterial thromboembolic events,
hypersensitivity to CHO cell products or other recombined
human or humanized antibodies. Written informed consent
was required from all patients.
Administration and dose escalation
Tanibirumab was administered intravenously to each patient
over 60 min on Days 1, 8, 15, every four weeks. We designed
the study to escalate tanibirumab at 9 different dose levels
from 1mg/kg to 28 mg/kg with a 3 + 3 method. Three patients
were accrued to each dose level. If none of the three patients
experienced DLT, the dose was increased in a subsequent
group of three patients. If DLT occurred in 1 of the 3 initial
patients at a particular dose level, then 3 additional patients
were treated at the same dose level, resulting in a total of six
patients. If a DLT developed in 2 of 6 patients, then enrollment
was stopped at this dose level, which was then defined as the
MTD. The preceding dose level was designated as the recom-
mended dose for the phase II study. If two of the first 3 patients
experienced DLT, then dose escalation was stopped and de-
escalated to an intermediate dose. If fewer than two of the six
patients experienced DLTs in the last dose level, then this dose
level was recommended for the phase II study. Intra-patient
dose escalation was not allowed.
Dose limiting toxicity (DLT) and maximum tolerated dose
(MTD)
A DLT was defined as the occurrence of any of following
events during the first cycle of therapy: grade 4 thrombocyto-
penia, grade 4 neutropenia lasting over 7 days, grade 3 or 4
neutropenia accompanied by temperature ≥ 38 °C, grade 3 or
4 non-hematologic toxicity except for diarrhea, nausea,
vomiting that responded to standard supportive care. Safety
was assessed every week for the first cycle of treatment.
Adverse events were evaluated according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0. All adverse events were evaluated until
30 days after the last dose of tanibirumab.
Duration of treatment and follow-up
In the absence of treatment delays due to adverse events, treat-
ment continued for up to 1 year or until one of the following
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criteria was met: disease progression, intercurrent illness that
prevented further administration of treatment, unacceptable
adverse events and patient withdrawal. Patients were followed
for 6 months after removal from the study or until death,
whichever occurred first. Patients removed from the study
for unacceptable adverse events were followed until resolution
or stabilization of the adverse events.
Analysis groups
All patients who received any amount of tanibirumab were
included in the safety analyses. Patients were considered
evaluable for the purposes of dose-escalation decisions and
establishing the MTD if they satisfied either of the follow-
ing criteria: received at least two doses of tanibirumab and
completed study assessments through the DLT observation
window without experiencing a DLT or experienced a DLT
and were withdrawn from the study within the DLT obser-
vation window.
Radiological (chest X-ray, computed tomography) studies
to assess response were performed after every 2 cycles of
therapy until disease progression. Response definitions were
according to Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1. Progression-free survival (PFS) was defined
as the time from the date of treatment initiation to the date of
the first documentation of disease progression (by radiologic
or clinical) or death. Patients with progression-free status were
censored at the last date verifying survival. The Kaplan–Meier
method was used to estimate the median values of time-to-
event variable and progression-free survival (PFS).
Pharmacokinetic analysis
PK sampling was conducted at several time points; Cycle 1,
first dose, pre-, 30 min, 2, 4, 24, 72 h/ s dose, pre- and 30 min/
third dose, pre, 30 min, 2, 4, 24, 72, 168, 336 h and Cycle 2–
13, first dose, pre- and third dose 30 min and EOT visits. The
pharmacokinetic (PK) parameter estimates of tanibirumab af-
ter the first and third doses in cycle 1 were characterized by
non-compartmental methods. The following PK parameter
estimates were derived: area under the concentration-time
curve (AUC), peak concentration (Cmax), trough concentra-
tion (Cmin), clearance (CL), volume of distribution (Vd), and
terminal elimination half-lives (initial and final, respectively).
Biomarker study
Several potential biomarkers of angiogenesis were mea-
sured at several time points. The angiogenic factors we
evaluated are as follows: soluble VEGFR-1, angiopoietin-
1, angiopoietin-2, placental growth factor (PlGF), fibro-
blast growth factors (FGF), platelet-derived growth factor
(PDGF)-AB/BB, thrombospondin-2, granulocyte-colony
stimulating factor (G-CSF), hepatocyte growth factor
(HGF), soluble Tie-2, soluble VEGFR-2, VEGF-A, leptin,
follistatin, platelet endothelial cell adhesion molecule
(PECAM)-1, and interleukin (IL)-8.
Results
Patient characteristics
Twenty six patients were enrolled from to October 2011 to
September 2013. The baseline demographics for all patients
are shown in Table 1. The median age was 58 years (range,
27–75) and 20 patients (76.9%) were male. All patients except
one (N = 25, 96.1%) had good performance status (ECOG PS
0–1). The most common tumor type was rectal cancer
(N = 11), followed by colon cancer (N = 8), head and neck
Table 1 Patient characteristics (N = 26)










Rectal cancer 11 (42.3)
Colon cancer 8 (30.8)
Head and neck squamous cell carcinoma 2 (7.7)
Gastric cancer 1 (3.9)
Non-small cell lung cancer 1 (3.9)
Esophageal cancer 1 (3.9)
Adenoid cystic carcinoma 1 (3.9)
Malignant fibrous histiocytoma 1 (3.9)







Prior systemic regimens for metastatic disease
1 1(3.8)
≥ 2 25(96.2)





squamous cell carcinoma (N = 2) and patients with gastric
cancer, non-small cell lung cancer, esophageal cancer, adenoid
cystic carcinoma, malignant fibrous histiocytoma were en-
rolled one by one. Seven patients had a history of previous
bevacizumab treatment.
Dose escalation and DLT
Patient enrollment and treatment results are shown in
Fig. 1. DLT was assessed in 24 patients as two patients
were withdrawn before completion of the first cycle of
treatment due to ileus and foot fracture, respectively.
There was no DLT in a total of 8 dose levels. Even though
we planned 9 dose levels extending up to 28 mg/kg, we
stopped dose escalation at 24 mg/kg. This was due to the
pharmacokinetic results which showed that mean trough
concentrations exceeded the biologically relevant target
levels at 12 mg/kg and above, and because several heman-
giomas occurred. Consequently, the MTD of tanibirumab
was established to be 24 mg/kg.
Overall safety and tolerability
All adverse events in all cycles are shown in Table 2. The most
frequently reported drug-related adverse events were heman-
gioma (N = 15, 57.7%), followed by skin rash (N = 8, 30.8%),
itching (N = 5, 19.2%) and fatigue (N = 4, 15.4%). Severe
adverse events of grade 3 or 4 were observed in two patients
(7.7%), irrespective of their potential drug-related attribution.
These were neutropenia and spine pathologic compression
fracture. We observed hemangioma from dose level 2 (2 mg/
kg), usually at the end of cycle 1. Among 16 patients with
hemangioma, seven progressed to grade 2 hemangiomas and
their treatment was based on a physicians’ decision; temporal-
ly holding of tanibirumab, excision of hemangioma or obser-
vation. Six cases were pathologically confirmed through bi-
opsy. All hemangioma lesions regressed at 1–2 months after
discontinuation of tanibirumab.
Immunogenicity
Antibodies to tanibirumab were observed in four samples but
these had no neutralizing activity and the plasma concentra-
tions of tanibirumab were unaffected.
Pharmacokinetic analysis
Individual PK parameters, including mean trough and
other AUC parameters, were obtained from 26 patients
(Supplementary Table 1). Cmax and AUCinf increased
proportionately as the dose increased (Fig. 2). Half-
lives were 1.6–2.3 days and 1.5–3.0 days at first dose
and third dose, respectively, and the increases of Cmax
and AUC did not affect the half-life. As a result, PKs
were characterized by dose-dependent linear exposure
and mean trough concentrations exceeded biologically
relevant target levels at 12 mg/kg and above.




Among several factors, serum VEGF, soluble VEGFR-2, and
PlGF changed at the 4 mg/kg dose level and above (Fig. 3).
Efficacy and follow-up details
In total, 75 cycles were administered with a median of
two cycles (range, 1 ~ 10). All patients who completed













Total (n = 26)





Neutropenia 1 1 1 (3.8) 1 (3.8)
Anemia 1 1 (3.8)
Thrombocytopenia
Non-hematological
Anorexia 1 1 1 3 (11.5)
Nausea 1 1 2 (7.7)
Vomiting 2 1 3 (11.5)
Diarrhea 2 2 (7.7)
Mucositis 2 1 3 (11.5)
Myalgia 2 2 4 (15.4)
Fatigue 1 1 1 2 5 (19.2)
General weakness 1 2 3 (11.5)
Headache 1 1 2 (7.7)
Dizziness 1 1 2 (7.7)
Skin rash 1 4 2 2 9 (34.6)
Itching sense 2 2 2 6 (23.1)
Hemangioma 3 2 2 2 1 2 4 16 (61.5)
Edema 1 1 1 3 (11.5)




Fig. 2 Mean serum
concentration time profiles for
tanibirumab
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at least two cycles of therapy were considered evaluable
for treatment response (N = 18). Among the 18 patients
in the efficacy set, no objective response was observed,
however, 11 patients showed stable disease with a dis-
ease control rate of 61.1% (95% C.I: 38.6–83.6%). Three
patients had stable disease for more than 6 months, in-
cluding patients with adenoid cystic carcinoma, rectal
cancer and colon cancer. The median progression-free
survival was 3.0 months (95% C.I: 1.9–4.0). Brief
Individual data of patients were given on Fig. 4.
Fig. 3 Pharmacodynamic study,
scatterplots of VEGF-A, soluble
VEGFR-2 and PIGF of raw data
from pretreatment values over
time after infusion of tanibirumab
Fig. 4 Swimmerplot of individual patient data
Invest New Drugs
Discussion
Tanibirumab was developed to inhibit angiogenesis through
binding to VEGFR2 with high affinity. Tanibirumab, a fully
human monoclonal antibody, selectively binds to VEGFR2
and neutralizes the biological activity of VEGFR2. It there-
fore blocks angiogenesis and inhibits tumor growth and
metastasis. Whereas bevacizumab specifically binds to
VEGF-A only, tanibirumab blocks all known VEGFs from
binding to VEGFR2, which might result in improved clin-
ical efficacy.
In the present study, tanibirumab was well tolerated as a
weekly infusion. Even though we initially planned 9 dose
levels up to 28 mg/kg, we stopped dose escalation at 24 mg/
kg. This was due to the pharmacokinetic results which showed
that mean trough concentrations exceeded biologically rele-
vant target levels at 12 mg/kg and above, and due to several
occurrences of hemangioma. Target dose (Ctrough ≥ 20 μg/ml)
was previously determined in in vitro HUVEC and in vivo
COLO205 model studies. Consequently, the MTD of
tanibirumab was determined to be 24 mg/kg.
The tanibirumab PK profile was characterized by dose-
proportional elimination and linear exposure. In the PD
analysis, serum VEGF-A, soluble VEGFR-2, and PlGF
changed at the 4 mg/kg dose level and above. This effect
did not seem to be dose related. The increased VEGF-A
concentration is likely due to displacement of the receptor-
bound natural VEGF-A ligand after tanibirumab treatment.
Moreover, this may be a result of hypoxia due to inhibition
of the VEGF/VEGFR signaling pathway. Similar results
were previously reported in other VEGF/VEGFR inhibitor
studies [17–20], and VEGF-A elevation may be a useful
marker for VEGFR2 blockade. The concentration of
sVEGFR2 was dropped right after tanibirumab injection
and restored original level or increased somewhat. It is
similar tendency to that of ramucirumab [17]. Binding of
tanibirumab to sVEGFR2 may delay the washout of
sVEGFR2, which results in increment of sVEGFR2.
Several patients developed hemangiomas in our study.
Hemangiomas are formed by an abnormal collection of
blood vessels that may resemble tumors. They are usually
found on the skin or internal organs and can lead to dis-
figurement or life-threatening consequences [21, 22]. In
our study, all hemangioma events were grade 1 or 2 and
resolved upon cessation of tanibirumab administration.
Although one patient who had a hemangioma near a co-
lostomy site was withdrawn from the study due to the risk
of bleeding, it did not found in the internal organs and the
hemangiomas in other patients did not result in discontin-
uation of tanibirumab. The mechanism through which
hemangiomas develop is unclear, however, in the case of
infantile hemangioma, hypoxia, estrogen and VEGFR1/
VEGFR2 expression have been suggested as possible
causes [23, 24]. Hemangioma events were previously re-
ported in other VEGFR2 antibody studies. In a
ramucirumab study, one patient receiving 4 mg/kg
ramucirumab treatment developed a hemangioma [25].
In a phase I study of CDP-791, a PEGylated di-Fab’ con-
jugate that binds VEGFR2, seven of 31 patients devel-
oped hemangiomas [26]. The biopsy and immunohisto-
chemical staining of these hemangiomas showed that
VEGFR2 was widely expressed, but PEG was only pres-
ent in the parts of the sections that did not bind the anti-
phospho-VEGFR2 antibody, suggesting that the drug was
biologically active and thereby inhibited receptor activa-
tion and phosphorylation. In that study, the mechanism of
hemangioma was also inconclusive. However, we can hy-
pothesize about the involvement of two different path-
ways: the first being the VEGFR2 pathway and the sec-
ond being other angiogenic factors. Even though signaling
through VEGFR2 bound to tanibirumab is inhibited, free
VEGFR2 unbound to tanibirumab can be internalized into
cells and phosphorylated. This VEGFR2 signaling can
induce hemangioma when combined with certain local
circumstances [23]. An additional possible explanation is
that local hypoxia induced by tanibirumab may induce
many kinds of different angiogenic factors, which might
ultimately result in hemangioma. To further investigate
hemangioma events, biopsy and immunohistochemical
staining of many additional angiogenic factors will be
needed.
In summary, the anti-VEGFR2 antibody tanibirumab
was well tolerated and showed signs of clinical activity in
multiple solid tumors. Based on the pharmacokinetic/
safety profiles of tanibirumab, a phase II study could em-
ploy dosing schedules of 12 mg/kg - 24 mg/kg every week
or 20 mg/kg - 24 mg/kg every two weeks. Similar to other
anti-VEGFR/VEGFR agents, predictive biomarkers of
clinical benefit have not been identified and should be fur-
ther investigated.
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